Medical Devices - Cardiovascular/Venous Intervention
Strategic Profile
As a late clinical-stage company, enVVeno is developing both surgical and non-surgical replacement venous valves for severe chronic venous insufficiency in the deep venous system. The company is positioned to establish itself as a global leader in severe deep venous disease treatment.
Cyborg Score Rationale
The company has a market cap of approximately $6.5 million with negative earnings and substantial burn rate, indicating it is pre-revenue and capital-constrained. As of December 2025, the company had approximately $28 million in cash and investments but faced prior compliance issues with Nasdaq listing standards, which were resolved in February 2026.
Top Insights
enVVe represents a non-surgical, transcatheter-based valve system that could provide less invasive treatment option compared to VenoValve.
VenoValve is currently undergoing evaluation in a U.S. pivotal study, a critical regulatory milestone.
Company regained Nasdaq compliance after stock price recovery in early 2026, reducing delisting risk.
With only 37 employees as of February 2026, enVVeno operates as a lean clinical-stage organization.
Named Competitors
Boston Scientific Vascular Solutions — Established vascular intervention devices
Medtronic Cardiovascular — Large-cap cardiovascular device company